Hugo, Versius, and Ottava Don't Claim Autonomy. Da Vinci Does, Barely.
Updated: Aug 30
Surgical robotics marketing leans hard on words like intelligence and AI-powered.
Autonomy is a different word, and almost nobody in the field actually uses it.
Checking four companies' public claims against their FDA filings turns up a finding most people wouldn't expect: the overclaiming risk in this space is smaller at the source than it looks downstream.
Hugo and Versius disclaim more than they claim
Medtronic's Hugo RAS received FDA clearance for urologic procedures in December 2025.
Its marketing centers on a digital ecosystem called Touch Surgery, built around training tools and post-operative case insights.
Medtronic's own product material states plainly that these AI features are not intended to direct surgery or aid in diagnosis.
That's a company explicitly disclaiming autonomy in its own documentation, not overselling it.
CMR Surgical's Versius tells a similar story.
Versius Plus received 510(k) clearance in December 2025 for cholecystectomy, and its marketing leans on words like "intelligence" and a data-driven ecosystem.
Read closely, none of CMR's public claims assert autonomous decision-making or task execution.
Both systems sit at L1 on the Autonomy Ladder: assistance and data infrastructure layered onto a surgeon-controlled instrument.
Ottava's claim needs one scope note
Johnson & Johnson's Ottava received FDA De Novo authorization on July 22, 2026, for ten named general surgery procedures in the upper abdomen.
The company's marketing highlights "automated procedural setups," a phrase worth reading carefully.
That automation refers to the table and arms repositioning together, not the system performing any part of the surgical task itself.
Ottava's claim language stays inside L1 to L2, the same territory as Hugo and Versius.
Da Vinci is the one real exception
Intuitive Surgical is the only company in this audit using the word "autonomy" in an official framework.
In July 2026, the company outlined a five-layer AI roadmap topped by what it calls "supervised autonomy."
Intuitive frames that top layer as a long-term vision, not a feature built into any currently cleared da Vinci system.
That distinction is real, but it's also the one place in this audit where careful source language could get flattened into a bigger claim on the way to a headline.
A full breakdown of that five-layer framework, layer by layer, lives in NextInSurgery's companion report on Intuitive's AI roadmap specifically.
The gap isn't where it looks
Across four companies, the pattern holds: claims stay close to what's actually cleared.
The bigger risk sits downstream, in how quickly "AI-powered" and "intelligence" get compressed into "autonomous" by press coverage and hospital marketing several steps removed from the FDA filing.
That gap, between careful source language and looser summary, is the throughline of NextInSurgery's full claims audit.
For a full breakdown of what each company claims versus what its FDA filings support, see the Autonomy Claims Audit.
Source: Medtronic newsroom · CMR Surgical · J&J MedTech · GlobeNewswire
